RxDoctor Payments Data

Amanda Evans

Family · Greer, SCNPI 1154752780

Payments from drug & device makers

$5,975in general payments, 2019–2025

Across 407 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$895
  • AbbVie$860
  • AstraZeneca$562
  • Lilly USA, LLC$457
  • Boehringer Ingelheim$369
  • Amgen$266
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,90699%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,975 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$78,964
Medicare patients
140
Services billed
1,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$42,542
JardianceEmpagliflozin26$42,187
EliquisApixaban37$42,147
FarxigaDapagliflozin Propanediol27$25,656
Nurtec OdtRimegepant Sulfate13$17,231
TrulicityDulaglutide12$16,715
Tresiba Flextouch U-200Insulin Degludec21$16,451
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,369
XareltoRivaroxaban11$12,506
Tresiba Flextouch U-100Insulin Degludec18$11,823
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,130
SymbicortBudesonide/Formoterol Fumarate11$3,354
Albuterol Sulfate HfaAlbuterol Sulfate66$1,907
Atorvastatin Calcium201$1,825
Duloxetine Hcl48$1,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$253$59,37850 claims
Novo NordiskOzempic$895$42,54236 claims
Boehringer IngelheimJardiance$369$42,18726 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$562$37,14149 claims
Lilly USA, LLCTrulicity$457$16,71512 claims
GSKTrelegy Ellipta$234$16,36918 claims
AbbVieSynthroid$860$1,19713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →